Table 1 Characteristics of enrolled patients
Variables | Number (total samples = 629) |
|---|---|
Sexual, M/F | 244 (38.79%) /385 (61.21%) |
Age, y | 46.71 ± 10.33 |
Weight, kg | 160.41 ± 7.77 |
High, cm | 57.49 ± 9.92 |
Smoking habit | 67 (10.65%) |
Drinking history | 36 (5.72%) |
Combined diseases | |
 Hypertension | 58 (9.22%) |
 CHD | 19 (3.02%) |
 T2D | 13 (2.07%) |
 AF | 268 (42.61%) |
 Stroke history | 28 (4.45%) |
 Infectious endocarditis | 30 (4.77%) |
 Digestive tract disease | 14 (2.23%) |
 Gallbladder disorders | 21 (3.34%) |
 Hepatitis | 17 (2.70%) |
 Hyperthyroidism | 16 (2.54%) |
 Pausimenia | 93 (14.79%) |
MHVR | 556 (88.39%) |
BHVR | 73 (11.61%) |
MAZE | 99 (15.74%) |
AF after Surgery | 169 (26.87%) |
Drugs increase INR | 23 (3.66%) |
Drugs decrease INR | 0 |
Follow-up time, media (25th-75th IQR), day | 291 (225–442) |
INR measurements, media (25th-75th IQR) | 9 (7–11) |
INR > 4 | 229(36.40%) |
INR > 100 | 19 (3.02%) |
PTTR (6 M) | 55.88 ± 25.0 |
PTTR (6 M) > 80% | 125 (19.87%) |
PTTR (6 M) > 60% | 288 (45.79%) |
PTTR (6 M) < 40% | 183 (29.09%) |
VKORC1 -1639AA | 520 (82.67%) |
VKORC1 -1639AG | 104 (16.53%) |
VKORC1 -1639GG | 5 (0.79%) |
CYP2C9 *1*1 | 574 (91.26%) |
CYP2C9 *1*3 /*3*3 | 55 (8.74%) |